Johnson & Johnson
JNJ
$238.46
-1.18%
Johnson & Johnson is the world's largest and most diverse healthcare firm, operating through two core divisions: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). The company is a global leader and a dominant force in the healthcare industry, distinguished by its scale, diversified portfolio, and post-2023 restructuring into a pure-play healthcare entity following the Kenvue consumer business spin-off. The current investor narrative is heavily focused on the company's strategic positioning amid new U.S. drug pricing policies and its pipeline execution, with recent headlines highlighting FDA approvals for key drugs like its oral psoriasis treatment and multiple myeloma combo therapy, which are seen as vital growth drivers to offset patent expirations and competitive pressures.…
JNJ
Johnson & Johnson
$238.46
Related headlines
Investment Opinion: Should I buy JNJ Today?
Rating & Thesis: JNJ is a Hold. The core thesis is that the stock's defensive qualities, strong cash flow, and successful pipeline execution are already largely reflected in its price following a 60% one-year rally, leaving limited near-term upside without a clear new catalyst. Analyst sentiment is bullish (with recent upgrades), but the stock is consolidating near its 52-week high.
Supporting Evidence: The valuation at a forward P/E of 18.96x is reasonable but not compelling for a company with 9% revenue growth. The PEG ratio of 0.21 suggests undervaluation, but this metric can be distorted by one-time items. Profitability is excellent (32.87% ROE, 20.83% net margin), and the balance sheet is rock-solid (D/E 0.59). The implied upside to the 52-week high of $251.71 is only about 5.5%, indicating limited near-term runway.
Risks & Conditions: The two biggest risks are competitive pressure in immunology/oncology and potential multiple compression if growth slows. This Hold would upgrade to a Buy if the stock pulls back meaningfully (e.g., below $220, offering a better entry yield and valuation) or if Q1 2026 earnings demonstrate accelerating growth from new launches. It would downgrade to a Sell if revenue growth decelerates below 5% or if net margins contract significantly. The stock is currently fairly valued relative to its own history and defensive profile.
Sign up to view all
JNJ 12-Month Price Forecast
JNJ presents a classic 'steady-eddie' investment profile with limited near-term excitement but substantial downside protection. The 12-month outlook is one of range-bound consolidation, with the base case (60% probability) seeing the stock trade between $235 and its 52-week high of $251.71. The bull case requires flawless pipeline execution in a favorable regulatory environment, while the bear case hinges on competitive setbacks. The stance would upgrade to bullish on a pullback to the low $220s, improving the risk/reward, or on clear evidence of revenue acceleration above 10%. It would turn bearish if quarterly growth decelerates meaningfully below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Johnson & Johnson's 12-month outlook, with a consensus price target around $310.00 and implied upside of +30.0% versus the current price.
Average Target
$310.00
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$191 - $310
Analyst target range
Analyst coverage for this large-cap blue-chip is robust, with 15 analysts providing estimates. The consensus sentiment leans bullish, as evidenced by recent institutional actions including upgrades to 'Overweight' from Morgan Stanley and maintained 'Buy' or 'Outperform' ratings from firms like RBC Capital, HSBC, and Citigroup. The average target price implied by earnings estimates is not explicitly stated, but the estimated EPS range for the forward period is $16.26 to $17.24, with an average of $16.86. The wide target range signals some uncertainty, likely reflecting debates over drug pricing headwinds, pipeline execution, and the macroeconomic impact of potential tariffs. The high-end estimates likely assume successful commercial execution of new drug launches and sustained margin performance, while the low-end may factor in competitive pressures and regulatory risks. The pattern of recent analyst actions shows a generally stable to positive bias, reinforcing the stock's status as a core healthcare holding with a favorable risk-reward profile according to the Street.
Bulls vs Bears: JNJ Investment Factors
The bull case for JNJ, anchored in strong fundamentals, pipeline wins, and reasonable valuation, currently holds stronger evidence than the bear case. The company's 9% revenue growth, $19.7B in annual FCF, and defensive profile provide a solid foundation. However, the stock's powerful 60% one-year rally brings it near technical resistance, introducing near-term risk. The single most important tension in the investment debate is whether JNJ's new drug launches (Icotyde, Tecvayli) can generate sufficient growth to fully offset competitive and regulatory headwinds while justifying its valuation, which is no longer deeply discounted. The resolution of the U.S. drug tariff situation will be a critical near-term catalyst for sentiment.
Bullish
- Strong Revenue Growth & Profitability: Q4 2025 revenue grew 9.08% YoY to $24.56B, with a robust net margin of 20.83%. The company generates massive free cash flow of $19.70B TTM, funding growth and shareholder returns.
- Pipeline Execution & FDA Approvals: Recent FDA approvals for the oral psoriasis drug Icotyde and the Tecvayli multiple myeloma combo therapy provide significant new growth drivers. These are vital to offset patent expirations and competitive pressures.
- Attractive Valuation Post-Run-Up: The trailing P/E of 18.81x is below recent highs (e.g., 24.63x in Q4 2025), suggesting a more reasonable entry point after the 60% one-year gain. The PEG ratio of 0.21 indicates potential undervaluation relative to growth.
- Defensive Profile & Low Volatility: With a beta of 0.329, JNJ is approximately 67% less volatile than the market. This defensive characteristic, combined with a 2.46% dividend yield, makes it a core holding for risk-averse portfolios.
Bearish
- Potential Tariff & Regulatory Headwinds: Recent news highlights 100% tariffs on imported drugs for companies without pricing deals. While JNJ may be shielded, this creates sector-wide uncertainty and potential margin pressure from U.S. drug pricing policies.
- Technical Overextension Near 52-Week High: Trading at $238.46, JNJ is near 88% of its 52-week range ($146.12-$251.71). The 1-month return of -1.86% signals a short-term pullback, suggesting the stock may be overextended and due for consolidation.
- Intense Competitive Pressure in Key Markets: Competitors like AbbVie are posting strong clinical results (e.g., 55% remission for Skyrizi in Crohn's), directly challenging JNJ's position in the lucrative immunology market, which is a primary growth driver.
- Valuation Compression Risk: The forward P/E of 18.96x is slightly higher than the trailing P/E, indicating stable but not accelerating earnings expectations. Any growth disappointment could lead to multiple compression from current levels.
JNJ Technical Analysis
The stock is in a sustained, powerful uptrend, evidenced by a 60.37% gain over the past year. With a current price of $238.46, it is trading at approximately 88% of its 52-week range ($146.12 to $251.71), positioning it near the upper bounds of its yearly performance. This proximity to the high suggests strong momentum but also raises questions about potential overextension and the need for consolidation before attempting a breakout. Recent momentum shows signs of deceleration and consolidation after a sharp run-up. While the 3-month return remains robust at +16.67%, the 1-month performance has turned negative at -1.86%, indicating a short-term pullback within the larger uptrend. This divergence could signal a healthy pause for the stock to digest its significant gains, especially given its relative strength versus the S&P 500, which is up only 0.46% over the past month. Key technical support is anchored at the 52-week low of $146.12, though more immediate support likely resides near recent pullback lows around $235. Resistance is clearly defined at the 52-week high of $251.71. A decisive breakout above this level would signal a resumption of the primary bull trend, while a sustained breakdown below the $235 area could indicate a deeper correction. The stock's low beta of 0.329 indicates it is approximately 67% less volatile than the broader market, which is typical for a large-cap, defensive healthcare name and suggests lower risk for position sizing.
Beta
0.33
0.33x market volatility
Max Drawdown
-12.7%
Largest decline past year
52-Week Range
$146-$252
Price range past year
Annual Return
+60.4%
Cumulative gain past year
| Period | JNJ Return | S&P 500 |
|---|---|---|
| 1m | -1.9% | +2.6% |
| 3m | +16.7% | -2.3% |
| 6m | +25.0% | +2.6% |
| 1y | +60.4% | +27.3% |
| ytd | +15.0% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JNJ Fundamental Analysis
Revenue growth has been solid, with the most recent Q4 2025 revenue of $24.56 billion representing a 9.08% year-over-year increase. The multi-quarter trend shows consistent top-line expansion, with Q4 revenue up sequentially from Q3's $23.99 billion. The Innovative Medicine segment, at $15.76 billion in the latest period, is the primary growth driver, significantly outpacing the MedTech segment's $8.80 billion, highlighting the strategic focus on high-margin pharmaceuticals. The company is highly profitable, posting a Q4 2025 net income of $5.12 billion. Gross margins are exceptionally strong at 86.37% for the quarter, though this is elevated due to the post-Kenvue spin-off mix; the trailing twelve-month gross margin is a still-healthy 72.78%. Net margin for the quarter was 20.83%, demonstrating the company's ability to convert robust revenue into substantial bottom-line earnings. The balance sheet and cash flow profile are exceptionally strong, underpinning the company's financial health. Free cash flow over the trailing twelve months is a massive $19.70 billion, providing ample internal funding for growth initiatives, dividends, and share repurchases. The debt-to-equity ratio is a conservative 0.59, indicating a prudent capital structure. Furthermore, the company's return on equity is impressive at 32.87%, showcasing efficient use of shareholder capital.
Quarterly Revenue
$24.6B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.86%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JNJ Overvalued?
Given the company's substantial and consistent profitability, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE stands at 18.81x, while the forward PE is slightly higher at 18.96x. The minimal gap between trailing and forward multiples suggests the market is pricing in stable, but not accelerating, earnings growth expectations. Compared to its own historical range, the current trailing PE of 18.81x sits below the multi-year highs seen in recent quarters (e.g., 24.63x in Q4 2025 and 36.20x in Q3 2024) and is towards the lower end of its recent band. This positioning suggests the stock is not priced for excessive optimism relative to its own history, potentially offering a more reasonable entry point after its significant price appreciation. A direct industry average comparison is not available in the provided data, but the stock's valuation must be assessed in the context of its defensive characteristics, strong cash flow, and dividend yield of 2.46%. The PEG ratio of 0.21, based on trailing metrics, indicates the stock may be undervalued relative to its growth rate, though this figure requires careful interpretation given potential one-time impacts from the corporate restructuring.
PE
18.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1502x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: JNJ's primary financial risk is not leverage or liquidity—its debt-to-equity of 0.59 and $19.7B FCF are strengths—but rather margin pressure and growth dependency. The elevated Q4 gross margin of 86.37% is an artifact of the Kenvue spin-off and will normalize, potentially creating a headline earnings headwind. Furthermore, with the Innovative Medicine segment ($15.76B in Q4) driving nearly all growth, the company faces concentration risk if new drug launches underperform or face faster-than-expected competition, particularly in immunology and oncology.
Market & Competitive Risks: The stock trades at a forward P/E of 18.96x, which, while below its own recent highs, is not cheap for a large-cap healthcare stock with single-digit revenue growth, creating valuation compression risk if growth decelerates. Externally, the competitive landscape is intensifying, as seen with AbbVie's strong Skyrizi data challenging JNJ's immunology franchise. The looming threat of 100% U.S. tariffs on drug imports for companies without pricing deals, as per recent news, adds a layer of regulatory and macro uncertainty, though JNJ is likely among the shielded companies.
Worst-Case Scenario: The most damaging scenario would involve a combination of pipeline setbacks for key new drugs (Icotyde, Tecvayli), aggressive pricing actions from competitors like AbbVie eroding market share, and a broader sector de-rating due to sustained high interest rates. This could trigger analyst downgrades and a re-rating towards the lower end of its historical P/E range. The realistic downside could see the stock retreat to its 52-week low of $146.12, representing a potential loss of approximately -39% from the current price of $238.46. A more immediate bear-case target might align with the recent pullback support around $235, a drop of about -1.5%.
FAQ
The key risks are: 1) Competitive & Pipeline Risk: Intense competition in immunology (e.g., from AbbVie's Skyrizi) and potential underwhelming launches of new drugs like Icotyde. 2) Regulatory & Pricing Risk: Uncertainty around U.S. drug pricing policies and potential tariffs, which could impact sector margins and sentiment. 3) Valuation Risk: Trading near its 52-week high after a 60% run, the stock is susceptible to a pullback or multiple compression if growth decelerates. 4) Execution Risk: Successfully integrating the post-Kenvue pure-play healthcare strategy and delivering consistent growth from the Innovative Medicine segment.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $235 and $251.71, as steady execution meets expectations. The Bull Case (25% probability) targets $251.71 to $275, driven by blockbuster new drug launches and multiple expansion. The Bear Case (15% probability) sees a drop to $210-$235 on pipeline disappointments and competitive pressures. The most likely outcome is the Base Case, assuming JNJ maintains its current high-single-digit growth trajectory and stable margins. The average analyst EPS estimate for the forward period is $16.86.
JNJ is fairly valued relative to its own history and defensive profile. The trailing P/E of 18.81x sits below its recent multi-year highs (e.g., 24.63x), suggesting the significant price appreciation has been supported by earnings growth. The PEG ratio of 0.21 suggests potential undervaluation, but this can be misleading post-spin-off. Compared to the broader market, the stock is not cheap, but it is paying a fair price for its stability, strong cash flow ($19.7B FCF), and 2.46% dividend yield. The valuation implies the market expects steady, high-single-digit growth and no major operational missteps.
JNJ is a good buy for investors seeking a low-volatility, dividend-paying defensive stock for the long term. However, after a 60% one-year rally, the near-term upside appears limited to approximately 5.5% to its 52-week high. The valuation at a forward P/E of 18.96x is fair but not a bargain. The biggest downside risk is competitive pressure eroding growth, potentially leading to a pullback towards $235 or lower. It is a good buy on weakness for patient investors, but less attractive for those seeking high short-term returns.
JNJ is overwhelmingly suitable for long-term investment. Its low beta (0.329), reliable dividend (2.46% yield), and strong market positions make it an ideal core holding for building wealth over years. The stock is not well-suited for short-term trading due to its lower volatility and the fact that near-term catalysts (earnings, drug launches) are already closely watched by the market. Given its defensive characteristics and income component, a minimum holding period of 3-5 years is recommended to fully benefit from dividend compounding and navigate any interim volatility.